Northwest Biotherapeutics (NWBO) 5.41 $NWBO
Top Gainers Technical Data -- Research on Northwest Biotherapeutics, Midstates Petroleum, AVEO Pharma, and Infinity Pharma
PR Newswire - Mon May 12, 7:21AM CDT
The US markets saw a positive sentiment on Friday, May 09, 2014, with the NASDAQ Composite closing at 4,071.87, up 0.50%, the Dow Jones Industrial Average ending the session at 16,583.34, up 0.20% and the S&P 500 edging 0.15% higher to finish the trading session at 1,878.48. The session saw a positive impact from Consumer Discretionary, Health Care and Consumer Staples sectors along with a drag from Financials, Energy and Utilities sectors. A number of stocks saw large movements, including Northwest Biotherapeutics Inc. (NASDAQ: NWBO), Midstates Petroleum Company Inc. (NYSE: MPO), AVEO Pharmaceuticals Inc. (NASDAQ: AVEO) and Infinity Pharmaceuticals Inc. (NASDAQ: INFI). Free technical research on NWBO, MPO, AVEO and INFI can be downloaded upon signing up at:
Metastatic Ovarian Cancer - Pipeline Review, H1 2014: 7 Companies and 10 Drugs Profiled
M2 - Thu May 08, 3:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9f76g4/metastatic) has announced the addition of the "Metastatic Ovarian Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Ovarian Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Ovarian Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Ovarian Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved: - Daiichi Sankyo Company, Limited - Dainippon Sumitomo Pharma Co., Ltd. - Millennium Pharmaceuticals, Inc. - Aphios Corporation - Northwest Biotherapeutics, Inc. - VG Life Sciences, Inc. - Aura Biosciences, Inc. Drug Profiles: - tigatuzumab - orteronel - DCVax-L vaccine - Cell Therapy to Inhibit VEGFR-2 for Oncology - hydroxychloroquine sorafenib tosylate - APH-0912 - Drugs for Metastatic Ovarian Cancer - SM-276001 - Pseudovirions For Cancer - Glutathione Disulfide Liposomal For more information visit http://www.researchandmarkets.com/research/9f76g4/metastatic
PRESENTATION ON NW BIO'S DCVAX-DIRECT TRIAL ANNOUNCED FOR ASCO ANNUAL MEETING
PR Newswire - Tue Apr 22, 7:15AM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that ASCO (the American Society for Clinical Oncology) has announced in its Annual Meeting program that the Company will present its DCVax-Direct clinical trial and technology in a general poster session at this year's ASCO meeting, taking place in Chicago May 30 through June 3. The abstract is number TPS3133, and the poster is number 189(a).
NW BIO CLOSES ON FIRST $15 MILLION OF FINANCING FOR SUBSTANTIAL EXPANSION OF EUROPEAN PRODUCTION CAPACITY
PR Newswire - Tue Apr 15, 12:11PM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the closing of the first $15 million funding by a single institutional investor of the registered direct placement of up to $32 million which was announced by the Company last week. These first 2.27 million shares of common stock were sold for $6.60 per share.
Northwest Biotherapeutics expects USD32m in financing
M2 - Fri Apr 11, 7:05AM CDT
US-based biotechnology company Northwest Biotherapeutics (NWBO) said on Thursday that it has signed a registered direct placement of up to USD32m with a single institutional investor.
When is a Warrant Not a Warrant? When Northwest Bio is Raising Money.
at The Street - Thu Apr 10, 9:24AM CDT
An explanation of Northwest Bio's "up to" $32 million financing deal.
NW BIO ANNOUNCES FINANCING OF UP TO $32 MILLION
PR Newswire - Thu Apr 10, 7:15AM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that on April 9, 2014, it entered into an agreement with a single institutional investor for a registered direct placement of up to $32 million. The Stock Purchase Agreement provides for the sale of an initial $15 million of common stock at $6.60 per share (approximately 8% discount to the closing market price). The Stock Purchase Agreement also provides a non-transferable Oversubscription Option for the investor to purchase up to $17 million of common stock at $7.50 per share (approximately 5% premium to the closing market price) during the twelve months following the initial closing. There are no warrants in the financing.
NW BIO AGAIN SETS FEUERSTEIN RECORD STRAIGHT
PR Newswire - Mon Apr 07, 7:15AM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today again set the record straight: Adam Feuerstein's latest, sensationalized headline claims about the Company's annual report and Phase III trial are once again factually wrong and materially misleading.
Biotech Stock Mailbag: Celgene, IsoRay, Northwest Bio, Bubble Worries
at The Street - Fri Apr 04, 6:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
4 Stocks Under $10 Making Big Moves
at The Street - Wed Apr 02, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Northwest Bio, DCVax and 'Compassionate Use'
at The Street - Sat Mar 29, 10:33AM CDT
Northwest Biotherapeutics takes umbrage at anyone who describes the German Hospital Exemption decision for its brain cancer vaccine DCVax as "compassionate use" -- except when they do it.
Nasdaq stocks posting largest percentage decreases
AP - Fri Mar 28, 12:32PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
NW BIO REFUTES FURTHER FALSE AND MISLEADING CLAIMS BY FEUERSTEIN
PR Newswire - Fri Mar 28, 12:03PM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today refuted false and misleading claims by Adam Feuerstein in an article posted Thursday, March 27, after NW Bio's public presentation of significant positive news about all of the Company's programs.
Technical Insight on Top Gainers -- Research on Signet Jewelers, Quicksilver Resources, Northwest Biotherapeutics, and Goodrich Petroleum
PR Newswire - Fri Mar 28, 10:00AM CDT
The US markets saw a negative sentiment on Thursday, March 27, 2014, with the NASDAQ Composite closing at 4,151.23, down 0.54%, the Dow Jones Industrial Average ending the session at 16,264.23, down 0.03% and the S&P 500 edging 0.19% lower to finish the trading session at 1,849.04. The losses were broad based as seven out of ten sectors ended the session in negative. During the session, Information Technology, Financials, and Consumer Discretionary sectors ended in negative, while some positive momentum were observed in the Telecommunication Services, Energy, and Utilities sectors. A number of stocks saw large movements, including Signet Jewelers Ltd (NYSE: SIG), Quicksilver Resources Inc. (NYSE: KWK), Northwest Biotherapeutics Inc. (NASDAQ: NWBO) and Goodrich Petroleum Corp. (NYSE: GDP). Free technical research on SIG, KWK, NWBO and GDP can be downloaded upon signing up at:
Why Northwest Biotherapeutics, Orthofix International, and Conn's Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 27, 4:15PM CDT
Despite today's economic data being mixed, it predominantly leaned toward being better than expected. Yet, the broad-based S&P 500 still pushed lower on the day. Perhaps no piece of economic data stood out more than the final estimate of...
Northwest Bio CEO Discloses More Problems With DC-Vax Brain Cancer Study
at The Street - Thu Mar 27, 3:21PM CDT
Northwest Biotherapeutics CEO Linda Powers took to a podium at a conference in New York this afternoon and dribbled out some new information about the company's cancer vaccine DC-Vax and the ongoing phase III study in brain cancer. Powers is a...
Northwest Biotherapeutics To Present At The 4th Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference
PR Newswire - Thu Mar 27, 7:15AM CDT
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"
, a biotechnology company developing non-toxic DCVax® personalized immune therapies for cancer, announced today that Linda Powers, CEO, will present at the 4th Annual "Cancer Immunotherapy: A Long-Awaited Reality" conference being held at the New York Academy of Medicine in New York City on Thursday, March 27 at 2:45 pm ET. During her presentation, Ms. Powers will provide an overview of the Company's DCVax® cancer vaccine platform technology, product pipeline and clinical programs with DCVax-L and DCVax-Direct.
This Week in Biotech: NW Bio Soars While Geron Goes Geronimo
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 15, 2:15PM CDT
With the SPDR S&P Biotech Index up 59% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Top Gainers Technical Data -- Research on Northwest Biotherapeutics, Midstates Petroleum, AVEO Pharma, and Infinity Pharma
PR Newswire - Mon May 12, 7:21AM CDT
The US markets saw a positive sentiment on Friday, May 09, 2014, with the NASDAQ Composite closing at 4,071.87, up 0.50%, the Dow Jones Industrial Average ending the session at 16,583.34, up 0.20% and the S&P 500 edging 0.15% higher to finish the trading session at 1,878.48. The session saw a positive impact from Consumer Discretionary, Health Care and Consumer Staples sectors along with a drag from Financials, Energy and Utilities sectors. A number of stocks saw large movements, including Northwest Biotherapeutics Inc. (NASDAQ: NWBO), Midstates Petroleum Company Inc. (NYSE: MPO), AVEO Pharmaceuticals Inc. (NASDAQ: AVEO) and Infinity Pharmaceuticals Inc. (NASDAQ: INFI). Free technical research on NWBO, MPO, AVEO and INFI can be downloaded upon signing up at:
Metastatic Ovarian Cancer - Pipeline Review, H1 2014: 7 Companies and 10 Drugs Profiled
M2 - Thu May 08, 3:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9f76g4/metastatic) has announced the addition of the "Metastatic Ovarian Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Ovarian Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Ovarian Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Ovarian Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved: - Daiichi Sankyo Company, Limited - Dainippon Sumitomo Pharma Co., Ltd. - Millennium Pharmaceuticals, Inc. - Aphios Corporation - Northwest Biotherapeutics, Inc. - VG Life Sciences, Inc. - Aura Biosciences, Inc. Drug Profiles: - tigatuzumab - orteronel - DCVax-L vaccine - Cell Therapy to Inhibit VEGFR-2 for Oncology - hydroxychloroquine sorafenib tosylate - APH-0912 - Drugs for Metastatic Ovarian Cancer - SM-276001 - Pseudovirions For Cancer - Glutathione Disulfide Liposomal For more information visit http://www.researchandmarkets.com/research/9f76g4/metastatic
PRESENTATION ON NW BIO'S DCVAX-DIRECT TRIAL ANNOUNCED FOR ASCO ANNUAL MEETING
PR Newswire - Tue Apr 22, 7:15AM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that ASCO (the American Society for Clinical Oncology) has announced in its Annual Meeting program that the Company will present its DCVax-Direct clinical trial and technology in a general poster session at this year's ASCO meeting, taking place in Chicago May 30 through June 3. The abstract is number TPS3133, and the poster is number 189(a).
NW BIO CLOSES ON FIRST $15 MILLION OF FINANCING FOR SUBSTANTIAL EXPANSION OF EUROPEAN PRODUCTION CAPACITY
PR Newswire - Tue Apr 15, 12:11PM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the closing of the first $15 million funding by a single institutional investor of the registered direct placement of up to $32 million which was announced by the Company last week. These first 2.27 million shares of common stock were sold for $6.60 per share.
Northwest Biotherapeutics expects USD32m in financing
M2 - Fri Apr 11, 7:05AM CDT
US-based biotechnology company Northwest Biotherapeutics (NWBO) said on Thursday that it has signed a registered direct placement of up to USD32m with a single institutional investor.
When is a Warrant Not a Warrant? When Northwest Bio is Raising Money.
at The Street - Thu Apr 10, 9:24AM CDT
An explanation of Northwest Bio's "up to" $32 million financing deal.
NW BIO ANNOUNCES FINANCING OF UP TO $32 MILLION
PR Newswire - Thu Apr 10, 7:15AM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that on April 9, 2014, it entered into an agreement with a single institutional investor for a registered direct placement of up to $32 million. The Stock Purchase Agreement provides for the sale of an initial $15 million of common stock at $6.60 per share (approximately 8% discount to the closing market price). The Stock Purchase Agreement also provides a non-transferable Oversubscription Option for the investor to purchase up to $17 million of common stock at $7.50 per share (approximately 5% premium to the closing market price) during the twelve months following the initial closing. There are no warrants in the financing.
NW BIO AGAIN SETS FEUERSTEIN RECORD STRAIGHT
PR Newswire - Mon Apr 07, 7:15AM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today again set the record straight: Adam Feuerstein's latest, sensationalized headline claims about the Company's annual report and Phase III trial are once again factually wrong and materially misleading.
Biotech Stock Mailbag: Celgene, IsoRay, Northwest Bio, Bubble Worries
at The Street - Fri Apr 04, 6:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
4 Stocks Under $10 Making Big Moves
at The Street - Wed Apr 02, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Northwest Bio, DCVax and 'Compassionate Use'
at The Street - Sat Mar 29, 10:33AM CDT
Northwest Biotherapeutics takes umbrage at anyone who describes the German Hospital Exemption decision for its brain cancer vaccine DCVax as "compassionate use" -- except when they do it.
Nasdaq stocks posting largest percentage decreases
AP - Fri Mar 28, 12:32PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
NW BIO REFUTES FURTHER FALSE AND MISLEADING CLAIMS BY FEUERSTEIN
PR Newswire - Fri Mar 28, 12:03PM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today refuted false and misleading claims by Adam Feuerstein in an article posted Thursday, March 27, after NW Bio's public presentation of significant positive news about all of the Company's programs.
Technical Insight on Top Gainers -- Research on Signet Jewelers, Quicksilver Resources, Northwest Biotherapeutics, and Goodrich Petroleum
PR Newswire - Fri Mar 28, 10:00AM CDT
The US markets saw a negative sentiment on Thursday, March 27, 2014, with the NASDAQ Composite closing at 4,151.23, down 0.54%, the Dow Jones Industrial Average ending the session at 16,264.23, down 0.03% and the S&P 500 edging 0.19% lower to finish the trading session at 1,849.04. The losses were broad based as seven out of ten sectors ended the session in negative. During the session, Information Technology, Financials, and Consumer Discretionary sectors ended in negative, while some positive momentum were observed in the Telecommunication Services, Energy, and Utilities sectors. A number of stocks saw large movements, including Signet Jewelers Ltd (NYSE: SIG), Quicksilver Resources Inc. (NYSE: KWK), Northwest Biotherapeutics Inc. (NASDAQ: NWBO) and Goodrich Petroleum Corp. (NYSE: GDP). Free technical research on SIG, KWK, NWBO and GDP can be downloaded upon signing up at:
Why Northwest Biotherapeutics, Orthofix International, and Conn's Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 27, 4:15PM CDT
Despite today's economic data being mixed, it predominantly leaned toward being better than expected. Yet, the broad-based S&P 500 still pushed lower on the day. Perhaps no piece of economic data stood out more than the final estimate of...
Northwest Bio CEO Discloses More Problems With DC-Vax Brain Cancer Study
at The Street - Thu Mar 27, 3:21PM CDT
Northwest Biotherapeutics CEO Linda Powers took to a podium at a conference in New York this afternoon and dribbled out some new information about the company's cancer vaccine DC-Vax and the ongoing phase III study in brain cancer. Powers is a...
Northwest Biotherapeutics To Present At The 4th Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference
PR Newswire - Thu Mar 27, 7:15AM CDT
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"
, a biotechnology company developing non-toxic DCVax® personalized immune therapies for cancer, announced today that Linda Powers, CEO, will present at the 4th Annual "Cancer Immunotherapy: A Long-Awaited Reality" conference being held at the New York Academy of Medicine in New York City on Thursday, March 27 at 2:45 pm ET. During her presentation, Ms. Powers will provide an overview of the Company's DCVax® cancer vaccine platform technology, product pipeline and clinical programs with DCVax-L and DCVax-Direct. This Week in Biotech: NW Bio Soars While Geron Goes Geronimo
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 15, 2:15PM CDT
With the SPDR S&P Biotech Index up 59% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
